Prime Medicine (PRME) Cash from Investing Activities (2021 - 2026)

Prime Medicine has reported Cash from Investing Activities for 6 years, with the latest figure at $43.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 190.89% year-over-year to $43.4 million; the trailing twelve-month figure through Mar 2026 stood at -$17.6 million (down 130.53% YoY), and the FY2025 full-year result was -$108.8 million, down 258.88% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $43.4 million, up from $28.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $50.3 million in Q3 2024, with the low at -$92.1 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$1.5 million across 5 years, with a median of $2.8 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 401.64% — and 2025, when it sank 282.99%.
• Prime Medicine's Cash from Investing Activities stood at -$13.7 million in 2022, then jumped by 401.64% to $41.3 million in 2023, then grew by 16.88% to $48.3 million in 2024, then slumped by 41.29% to $28.3 million in 2025, then jumped by 53.16% to $43.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $43.4 million (Q1 2026), $28.3 million (Q4 2025), and -$92.1 million (Q3 2025), per Business Quant data.